BioAtla
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 65
- Market Cap
- $86.5M
- Website
- http://www.bioatla.com
- Introduction
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT05808634
- Locations
- 🇺🇸
UC Irvine, Irvine, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Metastatic CancerHead and Neck CancerSquamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell Carcinoma of the Head and NeckRecurrent Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Biological: Evalstotug (BA3071)
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05271604
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Christiana Care Helen Graham Cancer Center, Newark, Delaware, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody (Currently Enrolling Patients With Nonsquamous or Recurrent NSCLC (Type IIB, IIIA, IV)
- Conditions
- MelanomaNSCLC
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05180799
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Piedmont West, Atlanta, Georgia, United States
CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Biological: PD-1 inhibitor
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04681131
- Locations
- 🇺🇸
City of Hope - Duarte, Duarte, California, United States
🇺🇸University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Irvine, California, United States
🇺🇸California Research Institute, Los angeles, California, United States
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
- Conditions
- MelanomaHead and Neck CancerNon Small Cell Lung CancerTriple Negative Breast Cancer
- Interventions
- Biological: PD-1 inhibitor
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT03504488
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸City of Hope - Duarte, Duarte, California, United States
🇺🇸University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States
- Prev
- 1
- 2
- Next
News
BioAtla's BA3182 Shows Tumor Shrinkage Across Multiple Cancer Types in Phase 1 Trial
BioAtla presented first-in-human Phase 1 data for BA3182, a dual-conditionally active bispecific T-cell engager targeting EpCAM and CD3, showing tumor reductions in five patients across different adenocarcinoma types.
BioAtla's Tab-cel Shows Promise in Refractory Head and Neck Cancer
BioAtla's Tab-cel demonstrated an overall response rate in heavily pretreated head and neck cancer patients, with 11 responses out of 29 evaluable patients.
BioAtla Highlights Promising Clinical Data and Financial Results in Q3 2024
BioAtla's ozuriftamab vedotin Phase 2 trial shows a 9-month median overall survival in heavily pretreated head and neck cancer patients, indicating potential efficacy.
Context Therapeutics Acquires Rights to BioAtla's Nectin-4 x CD3 TCE, BA3362, for up to $133 Million
Context Therapeutics has acquired the exclusive worldwide license to BioAtla's BA3362, a Nectin-4 x CD3 T-cell engager (TCE), for up to $133 million, including upfront and milestone payments.
BioAtla's Evalstotug (BA3071) Shows Promise in Advanced Solid Tumors
BioAtla's evalstotug (BA3071), a conditionally active anti-CTLA-4 biologic, demonstrates potential in treating advanced solid tumors, with updated Phase 1 study results to be presented at SITC 2024.